HIVE vs NUAI

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Jul 13, 2026

HIVE

54.5
AI Score
VS
HIVE Wins

NUAI

51.2
AI Score

Investment Advisor Scores

HIVE

55score
Recommendation
HOLD

NUAI

51score
Recommendation
HOLD

AI Analyst Insights

AI insights temporarily unavailable

Detailed Metrics Comparison

Metric HIVE NUAI Winner
Revenue 225.97M 326,455 HIVE
Net Income -72.11M -3.32M NUAI
Net Margin -31.9% -1017.1% HIVE
ROE -12.9% 120.9% NUAI
ROA -11.6% -33.4% HIVE
Total Assets 624.00M 9.93M HIVE
Cash 14.07M 1.03M HIVE
Current Ratio 1.74 0.51 HIVE

Relative Price Performance (Last 90 Days)

HIVE 1M: -4.7% · 3M: -21.3% NUAI 1M: -8.7% · 3M: +15.3%

Current Technical Phase

HIVE

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 52

RSI (14): 51.9 · Price: $3.03

NUAI

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 47

RSI (14): 46.6 · Price: $4.86

Fundamentals Snapshot

Metric HIVE NUAI
Market Cap
Forward P/E -5.9 -6.0
Trailing P/E
Revenue (TTM)
Revenue Growth 0.7% -0.8%
Gross Margin 0.4% 1.0%
Operating Margin -0.6% -455.7%
EPS -1.54 -1.03
Dividend Yield

Frequently Asked Questions

Based on our detailed analysis, HIVE is currently the stronger investment candidate, winning 6 of the key financial metrics based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.